148 related articles for article (PubMed ID: 24382184)
41. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma.
Warmann SW; Heitmann H; Teichmann B; Gratz KF; Ruck P; Hunger M; Fuchs J
Pediatr Hematol Oncol; 2005; 22(5):373-86. PubMed ID: 16020127
[TBL] [Abstract][Full Text] [Related]
42. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells.
Lee SY; Rhee YH; Jeong SJ; Lee HJ; Lee HJ; Jung MH; Kim SH; Lee EO; Ahn KS; Ahn KS; Kim SH
Environ Toxicol; 2011 Aug; 26(4):424-31. PubMed ID: 20196146
[TBL] [Abstract][Full Text] [Related]
43. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
Abulrob AN; Mason M; Bryce R; Gumbleton M
J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
[TBL] [Abstract][Full Text] [Related]
44. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
45. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
[TBL] [Abstract][Full Text] [Related]
46. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells.
Efferth T; Giaisi M; Merling A; Krammer PH; Li-Weber M
PLoS One; 2007 Aug; 2(8):e693. PubMed ID: 17668070
[TBL] [Abstract][Full Text] [Related]
47. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
48. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
49. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
Seebacher NA; Richardson DR; Jansson PJ
Br J Pharmacol; 2015 May; 172(10):2557-72. PubMed ID: 25586174
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of apoptosis is the cause of resistance to doxorubicin in human breast adenocarcinoma cells.
Osmak M; Brozović A; Ambriović-Ristov A; Hadzija M; Pivcević B; Smital T
Neoplasma; 1998; 45(4):223-30. PubMed ID: 9890665
[TBL] [Abstract][Full Text] [Related]
51. Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization.
Argov M; Bod T; Batra S; Margalit R
Eur J Pharm Sci; 2010 Sep; 41(1):53-9. PubMed ID: 20553861
[TBL] [Abstract][Full Text] [Related]
52. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
53. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J
J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543
[TBL] [Abstract][Full Text] [Related]
54. Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells.
Gatouillat G; Odot J; Balasse E; Nicolau C; Tosi PF; Hickman DT; López-Deber MP; Madoulet C
Cancer Lett; 2007 Nov; 257(2):165-71. PubMed ID: 17517470
[TBL] [Abstract][Full Text] [Related]
55. Circumvention of resistance to photodynamic therapy in doxorubicin-resistant sarcoma by photochemical internalization of gelonin.
Olsen CE; Berg K; Selbo PK; Weyergang A
Free Radic Biol Med; 2013 Dec; 65():1300-1309. PubMed ID: 24076428
[TBL] [Abstract][Full Text] [Related]
56. Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study.
Shahraki O; Edraki N; Khoshneviszadeh M; Zargari F; Ranjbar S; Saso L; Firuzi O; Miri R
Drug Des Devel Ther; 2017; 11():407-418. PubMed ID: 28243063
[TBL] [Abstract][Full Text] [Related]
57. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
58. Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells.
Lin ST; Chou HC; Chang SJ; Chen YW; Lyu PC; Wang WC; Chang MD; Chan HL
J Proteomics; 2012 Oct; 75(18):5822-47. PubMed ID: 22889595
[TBL] [Abstract][Full Text] [Related]
59. Different effects of magnetic field on drug activity in human uterine sarcoma cell lines MES-SA and MES-SA/Dx5.
Shibaki R; Kakikawa M
Electromagn Biol Med; 2022 Jul; 41(3):343-351. PubMed ID: 35793396
[TBL] [Abstract][Full Text] [Related]
60. Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.
Asakura T; Takahashi N; Takada K; Inoue T; Ohkawa K
Anticancer Drugs; 1997 Feb; 8(2):199-203. PubMed ID: 9073316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
